Aurin Biotech announced the development of a saliva test that can diagnose Alzheimer’s disease and predict future onset.
The non-invasive method is based on measuring salivary levels of amyloid-β protein terminating at position 42 (Aβ42); amyloid-β deposits in the brain typically indicate Alzheimer’s disease. Aβ42 is produced in all organs and is maintained at the same production rate through life. Studies have shown that these brain deposits begin 10 years or more before the clinical onset of Alzheimer’s disease.
In the study, 25 control patients (age range 15–92 years) showed Aβ42 levels in their saliva averaging 23.34pcg/mL, while in six Alzheimer’s disease patients the values ranged from 41.58–75.20pcg/mL. These Aβ42 levels were quantitated with ELISA type tests.
Study authors found that for healthy individuals, Aβ42 production rate was almost identical regardless of age or sex. In those at elevated risk of developing Alzheimer’s disease, however, rates were varied and were more than double that of normal individuals.
Dr Pat McGeer, President and CEO of Aurin Biotech, added, “If individuals know they are destined to develop Alzheimer disease, they can initiate preventive measures. These include taking over-the-counter non-steroidal anti-inflammatory drugs such as ibuprofen, drinking coffee, and sticking to a Mediterranean diet.”
For more information call (604) 224-6403 or visit AurinBiotech.com.
This article originally appeared on MPR